Aterian Q4 revenue $54.9M (-13.3% YoY), net loss $20.3M; reaffirms H2 2023 adj. EBITDA profitability target

Aterian, Inc.

Q4 2022 net revenue $54.9M, down 13.3% from $63.3M in Q4 2021.
Q4 gross margin fell to 37.1% from 45.6% due to liquidation of high-cost inventory.
Q4 adjusted EBITDA loss of $(16.2)M vs $(3.0)M in prior year.
Full year 2022 net loss $196.3M, including $120.4M goodwill impairment.
Q1 2023 revenue guidance $32-36M; reaffirms H2 2023 adj. EBITDA profitability.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Aterian, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Fourth quarter 2022 net revenue declined 13.3% to $54.9 million, compared to $63.3 million in the fourth quarter of 2021, net income Fourth quarter 2022 net loss of $(20.3) million declined from $(6.6) million in 2021. Full year 2022 net loss of $(196.3. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2022
Revenue: Fourth quarter 2022 net revenue declined 13.3% to $54.9 million, compared to $63.3 million in the fourth quarter of 2021
Net income: Fourth quarter 2022 net loss of $(20.3) million declined from $(6.6) million in 2021. Full year 2022 net loss of $(196.3
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 9, 2023, Aterian, Inc. (the “Company”) issued a press release announcing its financial results for the year-ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Aterian, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.